MediPharm Labs (LABS) Competitors C$0.08 -0.01 (-6.25%) As of 03:54 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesBuy This Stock LABS vs. CRDL, RX, HLS, SUGR, TGOD, NINE, WMD, MDP, DB, and HEXOShould you be buying MediPharm Labs stock or one of its competitors? The main competitors of MediPharm Labs include Cardiol Therapeutics (CRDL), BioSyent (RX), HLS Therapeutics (HLS), SugarBud Craft Growers (SUGR), Green Organic Dutchman (TGOD), Delta 9 Cannabis (NINE), WeedMD (WMD), Medexus Pharmaceuticals (MDP), Decibel Cannabis (DB), and HEXO (HEXO). These companies are all part of the "drug manufacturers - specialty & generic" industry. MediPharm Labs vs. Its Competitors Cardiol Therapeutics BioSyent HLS Therapeutics SugarBud Craft Growers Green Organic Dutchman Delta 9 Cannabis WeedMD Medexus Pharmaceuticals Decibel Cannabis HEXO MediPharm Labs (TSE:LABS) and Cardiol Therapeutics (TSE:CRDL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk. Does the media prefer LABS or CRDL? In the previous week, Cardiol Therapeutics had 1 more articles in the media than MediPharm Labs. MarketBeat recorded 1 mentions for Cardiol Therapeutics and 0 mentions for MediPharm Labs. MediPharm Labs' average media sentiment score of 0.00 equaled Cardiol Therapeutics'average media sentiment score. Company Overall Sentiment MediPharm Labs Neutral Cardiol Therapeutics Neutral Do insiders and institutionals have more ownership in LABS or CRDL? 0.7% of MediPharm Labs shares are held by institutional investors. Comparatively, 11.4% of Cardiol Therapeutics shares are held by institutional investors. 4.5% of MediPharm Labs shares are held by insiders. Comparatively, 4.6% of Cardiol Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has better earnings and valuation, LABS or CRDL? MediPharm Labs has higher revenue and earnings than Cardiol Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than MediPharm Labs, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMediPharm LabsC$39.42M0.79-C$12.05M-C$0.03-2.58Cardiol TherapeuticsN/AN/A-C$42.93M-C$0.51-3.32 Which has more risk & volatility, LABS or CRDL? MediPharm Labs has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500. Comparatively, Cardiol Therapeutics has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500. Is LABS or CRDL more profitable? Cardiol Therapeutics has a net margin of 0.00% compared to MediPharm Labs' net margin of -30.56%. MediPharm Labs' return on equity of -24.41% beat Cardiol Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets MediPharm Labs-30.56% -24.41% -7.17% Cardiol Therapeutics N/A -195.07%-54.15% SummaryMediPharm Labs beats Cardiol Therapeutics on 7 of the 11 factors compared between the two stocks. Get MediPharm Labs News Delivered to You Automatically Sign up to receive the latest news and ratings for LABS and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LABS vs. The Competition Export to ExcelMetricMediPharm LabsDrug Manufacturers IndustryMedical SectorTSE ExchangeMarket CapC$31.13MC$2.25BC$5.70BC$6.38BDividend YieldN/A2.92%3.77%6.72%P/E Ratio-2.584.2530.8669.99Price / Sales0.79684.80403.901,563.49Price / Cash1.3010.3725.2283.29Price / Book0.6811.269.514.96Net Income-C$12.05MC$20.70BC$3.26BC$301.20M7 Day PerformanceN/A1.18%4.49%1.05%1 Month PerformanceN/A4.73%5.18%2.05%1 Year PerformanceN/A3.29%31.98%27.82% MediPharm Labs Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LABSMediPharm LabsN/AC$0.08-6.3%N/A+14.3%C$31.13MC$39.42M-2.58130CRDLCardiol TherapeuticsN/AC$1.59+3.2%N/A-33.9%C$131.94MN/A-3.1220RXBioSyentN/AC$11.40flatN/A+14.1%C$130.39MC$34.06M18.50N/ANews CoverageHLSHLS Therapeutics0.4156 of 5 starsC$5.10+0.6%C$4.50-11.8%+58.9%C$113.46MC$40.13M-5.1191News CoverageAnalyst RevisionSUGRSugarBud Craft GrowersN/AC$13.25-1.8%N/A+55.9%C$90.37MC$575.64M15.9644TGODGreen Organic DutchmanN/AN/AN/AN/AC$89.95MC$31.37M-0.6541Gap UpHigh Trading VolumeNINEDelta 9 CannabisN/AC$1.03+3.0%N/A+0.0%C$89.36MC$12.87M19.07940News CoverageGap UpWMDWeedMDN/AC$0.28-1.8%N/A+0.0%C$67.82MC$27.53M-0.66628Gap UpMDPMedexus Pharmaceuticals2.4273 of 5 starsC$2.67-2.9%C$5.49+105.5%+25.5%C$59.78MC$100.25M12.7798News CoverageAnalyst RevisionGap UpDBDecibel CannabisN/AC$0.13+8.7%C$0.30+140.0%+100.0%C$51.13MC$105.60M-12.5083,000Gap DownHigh Trading VolumeHEXOHEXON/AN/AN/AN/AC$38.72MC$124.10M-0.26690 Related Companies and Tools Related Companies Cardiol Therapeutics Competitors BioSyent Competitors HLS Therapeutics Competitors SugarBud Craft Growers Competitors Green Organic Dutchman Competitors Delta 9 Cannabis Competitors WeedMD Competitors Medexus Pharmaceuticals Competitors Decibel Cannabis Competitors HEXO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (TSE:LABS) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersBiotech Alert: With news on MPox, RSV, and more, this tiny firm could disrupt a $3B marketA small biotech is stepping into the spotlight with a first-in-class antiviral platform—and it could be one of...Smallcaps Daily | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MediPharm Labs Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share MediPharm Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access